The CASP8 Knockout NCI-H1975 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human lung adenocarcinoma cell line NCI-H1975, featuring targeted disruption of the CASP8 gene encoding caspase-8. This polyclonal population provides a robust loss-of-function model for investigating caspase-8-dependent signaling without the constraints of single-cell clonal selection. The CRISPR/Cas9-mediated gene disruption eliminates full-length caspase-8 protein expression, enabling versatile studies into its roles in apoptosis, necroptosis, and inflammatory pathways. The polyclonal nature maintains genetic heterogeneity while ensuring functional knockout across the cellular pool, making it suitable for population-based assays.
NCI-H1975 is a human non-small cell lung cancer (NSCLC) epithelial cell line harboring both the EGFR L858R point mutation and the T790M gatekeeper mutation, which confer constitutive kinase activity and acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs), respectively. Derived from a lung adenocarcinoma, this cell line is a well-established model for studying EGFR-TKI resistance mechanisms and therapeutic strategies targeting resistant NSCLC. Its epithelial origin and defined genetic background provide a physiologically relevant context for examining cell death signaling and drug sensitivity in the presence of oncogenic EGFR signaling.
Caspase-8, encoded by CASP8, is an initiator caspase that is recruited to death-inducing signaling complexes (DISC) upon activation of death receptors such as FAS, TRAIL-R1/TNFRSF10A, TRAIL-R2/TNFRSF10B, and TNFR1 by their respective ligands FASLG, TNFSF10/TRAIL, and TNF. Within the DISC, caspase-8 interacts with the adaptor protein FADD and the regulatory protein c-FLIP, and upon proximity-induced dimerization and auto-proteolysis, it cleaves and activates effector caspases CASP3 and CASP7 to execute extrinsic apoptosis. Concurrent cleavage of the BH3-only protein BID generates truncated BID (tBID), which translocates to mitochondria to trigger the intrinsic apoptotic pathway. When caspase activity is inhibited, caspase-8 promotes necroptosis through the formation of a cytosolic complex containing RIPK1 and RIPK3, which phosphorylates MLKL, leading to membrane rupture and release of damage-associated molecular patterns such as HMGB1. Additionally, caspase-8 regulates NF-??B activation by interacting with TRAF2, cIAP1/2, and the IKK complex subunit NEMO (IKK??), thereby modulating transcription of pro-inflammatory cytokines including IL-1?? and IL-18. Caspase-8 also plays a role in Toll-like receptor signaling, further linking it to innate immunity.
In the NCI-H1975 background, which is a paradigm for studying acquired EGFR-TKI resistance, disruption of caspase-8 provides a critical tool to dissect the crosstalk between oncogenic EGFR signaling and death receptor pathways. This knockout model enables the investigation of how loss of caspase-8 affects sensitivity to TRAIL-based therapies, EGFR inhibitor-induced apoptosis, and the switch between apoptotic and necroptotic cell death in drug-resistant NSCLC cells. Moreover, the model facilitates studies on the role of caspase-8 in inflammatory signaling and its potential impact on the tumor microenvironment, as well as the evaluation of therapeutic agents targeting death receptors or downstream kinases. By eliminating caspase-8 function, researchers can assess the contribution of extrinsic apoptosis and necroptosis to drug response and disease progression in a clinically relevant mutational context.
Typical research applications for these polyclonal knockout cells include apoptosis and necroptosis mechanism studies, cancer drug resistance research focused on EGFR-TKIs, inflammatory and immune signaling analysis, and therapeutic target validation in NSCLC. Representative assays include Western blotting to confirm caspase-8 depletion and monitor cleavage of downstream targets such as CASP3 and CASP7, caspase-8 activity assays, apoptosis detection via Annexin V staining and TUNEL, necroptosis assessment through phospho-MLKL immunoblotting and HMGB1 release, co-immunoprecipitation for DISC complex components, RT-qPCR for NF-??B target genes, flow cytometry to quantify death receptor surface expression, and drug sensitivity assays using EGFR inhibitors or TRAIL receptor agonists. For further information about the CASP8 Knockout NCI-H1975 Polyclonal Cells, please contact Ascent Research.
